Instead, PAX3-FOXO1 translocation, an indicator of poor prognosis of alveolar rhabdomyosarcoma, is considered to be a treatment target; in preclinical study, PAX3-FOXO1 requires the BET bromodomain protein BRD4 to function at super enhances, so BRD4 inhibitor is suggested to be a new targeted drug for alveolar rhabdomyosarcoma [97,98]. Here, FOXO1 is linked to alveolar rhabdomyosarcoma.